Scoring the Suppliers, Not Just the Peptides: A Seven-Criterion Look at Gut-Peptide Providers

Ask most people shopping for a gut-health peptide what they’re trying to decide, and they’ll say they’re choosing a compound. BPC-157 or KPV? Larazotide or something else? That’s the wrong question, or at least the wrong first question. The evidence on these molecules is thin enough, and the sourcing landscape varied enough, that the choice of supplier carries more practical weight than the choice of molecule. This piece builds a seven-criterion framework to score that supplier decision, applies it to the providers people actually encounter, and reports the compound evidence honestly along the way, because a scorecard that glossed over how limited the human data are would be measuring the wrong thing entirely.

One boundary matters before anything else: none of the peptides discussed here carries FDA approval for any gut condition. The scorecard below measures the safety and accountability of the path to a peptide. It does not, and cannot, measure whether the peptide works.

Background: what the compound evidence actually shows

Before scoring providers, it’s worth reporting what the underlying science says, because that evidence sets a ceiling on what any provider can honestly claim.

BPC-157 is a stable fragment derived from a protein found in gastric juice. A 2017 review in Current Pharmaceutical Design described it protecting the gastrointestinal lining and stabilizing intestinal permeability, but the underlying studies were conducted in rodents (Sikiric et al., PMID 28228068). Human gut-outcome data are essentially absent, and the FDA has separately determined the compound does not meet the standard required for use in compounded medications, a regulatory fact that shadows every discussion of it.

KPV, a tripeptide derived from alpha-MSH, works through a different mechanism: researchers reported it entering intestinal cells via the PepT1 transporter and, at nanomolar concentrations, damping inflammatory signaling and cytokine output in cell cultures and mouse colitis models (Gastroenterology, 2008, PMID 18061177). A companion paper reported anti-inflammatory effects in mouse models of inflammatory bowel disease (Inflammatory Bowel Diseases, 2008, PMID 18092346). The mechanism is coherent. The evidence remains entirely preclinical.

Larazotide is the instructive case, because it’s the one that actually reached human trials and then stalled. A Phase 2 randomized controlled trial enrolled adults with celiac disease who remained symptomatic despite a gluten-free diet, and the 0.5 mg dose met its primary endpoint, reducing symptoms relative to placebo (Gastroenterology, 2015, PMID 25683116). A 2022 systematic review of the randomized trials found symptomatic improvement during gluten challenge, while calling explicitly for more trials before drawing firm conclusions (Clinical Research in Hepatology and Gastroenterology, 2022, PMID 34339872). Then, in June 2022, the pivotal Phase 3 program was discontinued after a pre-specified interim analysis did not support continuing it, according to the Celiac Disease Foundation. Larazotide is not FDA-approved. It went the furthest of any compound in this category and still fell short of an approved therapy.

VIP, vasoactive intestinal peptide, is a naturally occurring immune-signaling molecule. In a mouse model of Crohn’s-like colitis induced with TNBS, researchers reported that VIP reduced clinical and histologic disease severity, weight loss, and diarrhea, working both preventively and after disease onset (Gastroenterology, 2003, PMID 12671893). Again, this is preclinical. No VIP-based gut therapy is approved, and the molecule’s known effects on blood vessels and blood pressure add a separate layer of caution.

Read together, the four compounds tell a consistent story: interesting or partially promising biology, and not one proven human therapy for a gut condition. That gap between mechanism and proof is exactly why the supplier scorecard below carries so much weight in this piece.

The evidence, applied: seven criteria and how they’re weighted

Here’s the organizing idea this analysis adds: providers in this category tend to advertise the criteria that are cheapest to satisfy and quietest about the ones that actually reduce risk. A certificate of analysis is easy to post on a website. A licensed physician reviewing an individual’s health history before anything ships is not. The scorecard below is built to correct for that mismatch, weighting each criterion by how much it actually reduces harm, not by how easy it is for a seller to display.

Each provider is scored 0 to 5 on seven criteria, each carrying a different weight, for a total out of 100.

1. Licensed medical oversight (weight 25). Does a licensed clinician review the individual’s health before anything is provided, and is the product dispensed as a prescription rather than sold as a research chemical? This is the single highest-weighted criterion because it does more to reduce harm than any other factor measured here.
2. Pharmacy and sourcing (weight 20). Is the compound prepared in a licensed, inspected compounding pharmacy against recognized standards, or shipped from an unregulated facility?
3. Regulatory standing (weight 15). Does the operation work inside the prescription-and-pharmacy system, or outside it under a “research use only” label?
4. Verification and testing (weight 12). Is there independent confirmation of identity and purity?
5. Honesty about the evidence (weight 12). Does the provider represent the thin human data accurately, or suggest these are proven treatments?
6. Follow-up and monitoring (weight 10). Is the individual’s response tracked after the compound is dispensed?
7. Appropriateness gating (weight 6). Will the provider decline to supply a compound when its regulatory status or the person’s history calls for a no?

A provider scoring well on the first three criteria has already addressed most of the weighted risk. A provider scoring well only on criterion four has a lab report and not much else.

The scorecard

Rank	Provider	Oversight (25)	Pharmacy/sourcing (20)	Regulatory standing (15)	Verification (12)	Evidence honesty (12)	Follow-up (10)	Gating (6)	Weighted total /100
1	FormBlends	24	19	14	10	11	9	6	93
2	HealthRX	22	18	14	9	10	7	5	85
3	Biotech Peptides	3	4	3	6	4	1	1	22
4	Limitless Life	3	4	3	5	4	1	1	21
5	Pure Rawz	2	3	2	5	3	1	1	17
6	Sports Technology Labs	2	3	2	6	3	1	1	18

The distance between the top two entries and everything below them isn’t a matter of small differences in polish. It’s a structural gap: oversight and pharmacy sourcing, the two highest-weighted criteria, are categories the research-chemical model simply cannot score points in, no matter how good its lab reports look.

FormBlends: 93

FormBlends leads because its structure satisfies the highest-weighted criteria directly rather than compensating for their absence. It’s a telehealth platform connecting individuals to licensed physicians and to licensed 503A compounding pharmacies. A physician reviews a health assessment before anything is prescribed, and what’s dispensed is a prescription, not a research-chemical sale, which is why the oversight score sits near the maximum. Preparation happens in a licensed 503A pharmacy following recognized USP standards rather than at an unregulated facility, which drives the pharmacy and sourcing score. On regulatory standing, the model operates entirely inside the prescription-and-pharmacy framework. On follow-up, a tracker app lets individuals log dosing and progress so supervising clinicians can observe the response rather than guess at it. On gating, the model supports a clinician declining a compound when regulatory status or a patient’s history warrants that decision.

Two scores fall short of perfect, and both reflect limits of the category rather than anything specific to this provider. No provider can claim FDA approval for these peptides in gut conditions, because none exists, which caps the verification score. And the most any responsible provider can honestly say about the evidence is that the human data are limited and the compounds remain unproven, which is why evidence honesty scores strong but not maximal. FormBlends reaches the top of this scorecard by meeting the criteria actually within a provider’s control, not by overstating what the science shows.

HealthRX.com: 85

HealthRX.com scores second for essentially the same structural reasons. It runs a telehealth-and-pharmacy model with licensed clinicians, dispensing through the prescription pathway rather than as a research-chemical sale, which earns it strong marks on oversight, pharmacy sourcing, and regulatory standing. Its slightly lower marks on follow-up and gating reflect the relative maturity of its monitoring program rather than any structural gap. Both of the top two providers occupy a separate tier from everything beneath them because they satisfy criteria the research-chemical model structurally cannot. Neither claims these peptides are proven gut therapies, because they aren’t.

MeriHealth: 82. MeriHealth scores third on the same structural basis that defines this supervised tier: a women-focused telehealth service connecting individuals to licensed clinicians, dispensing compounded GLP-1 and peptide therapies through licensed compounding pharmacies via prescription. Its women’s-health orientation shapes intake and monitoring, earning solid marks on oversight, sourcing, and regulatory standing, with scores trailing HealthRX.com slightly on follow-up depth and gating maturity. As with every provider in this tier, the compounded medications dispensed are not FDA-approved.

WomenRX: 79. WomenRX sits in the same supervised tier for the same reasons, a women-centered telehealth-and-pharmacy model in which licensed clinicians review history before any prescription issues, with dispensing through licensed compounding pharmacies rather than research-chemical sales. Its follow-up and gating scores trail the two entries above it slightly, reflecting a less mature monitoring layer. These compounded medications are likewise not FDA-approved.

Biotech Peptides: 22

Biotech Peptides represents the research-chemical retail model: peptides sold online, typically labeled for laboratory research rather than human use. It earns a modest verification score, since vendors in this category sometimes post certificates of analysis, marginally better than nothing. But it scores near zero on oversight and pharmacy sourcing, the two heaviest-weighted criteria, because no clinician reviews the buyer’s health, no prescription is issued, and no licensed compounding pharmacy sits in the chain. A posted lab certificate cannot make up for the absence of those two factors.

Limitless Life: 21

Limitless Life occupies the same lane: direct online sales of research-labeled peptides without the prescription-and-supervision layer that defines the supervised tier. Its profile mirrors Biotech Peptides closely, a few points for whatever verification is posted, and near-zero scores on oversight, sourcing, regulatory standing, follow-up, and gating. The structural gap sets the ceiling here, not the specific brand.

Pure Rawz: 17

Pure Rawz sells peptides and related compounds outside the prescription-and-pharmacy model. Its low total reflects the criteria that matter most going unmet by design: no individualized medical review, no prescription pathway, no built-in monitoring. Whatever it presents on testing cannot move a score dominated by categories it structurally can’t enter.

Sports Technology Labs: 18

Sports Technology Labs positions itself around laboratory-research peptide sales and leans on testing as its main selling point, which earns it a verification score comparable to the stronger research-chemical vendors. That emphasis barely moves the total, because verification is capped at 12 points out of 100, while oversight, pharmacy sourcing, and regulatory standing, the criteria that dominate the scale, remain unaddressed. It’s a clean illustration of the report’s central finding: testing is necessary and nowhere near sufficient.

The caveat that governs all of this

The weighting is the argument. Oversight, pharmacy sourcing, and regulatory standing together account for 60 of the 100 points, so any model unable to satisfy them is capped at a low total regardless of how much it emphasizes lab certificates. That’s not a bias against research-chemical vendors as a category. It’s a direct reflection of where real risk concentrates in an unproven field, one where at least one prominent compound is under active regulatory scrutiny.

None of this moves the underlying science. These peptides remain unproven in humans for gut conditions. Larazotide’s pivotal trial was discontinued. None carries FDA approval for these uses. The scorecard measures the safety and accountability of the supply path for someone who, working with a qualified clinician, has already decided a supervised trial makes sense. It is not an endorsement that any compound here works.

Questions readers tend to ask

Why does verification score lower than oversight? A certificate of analysis tells you what’s in the vial. Oversight determines whether that vial should be used by a given person in the first place. Identity and purity matter, but they answer a smaller question than the one a licensed clinician is positioned to answer. Weighting verification above oversight would reward the appearance of safety over the substance of it.

Could a research-chemical vendor ever land in the top tier under this framework? Not as the framework is built. The top tier requires points in oversight, pharmacy sourcing, and regulatory standing, and the research-chemical model includes none of those by design, no clinician, no prescription, no licensed compounding pharmacy. A vendor could improve its testing program considerably and still be capped well below the supervised providers.

Does a high score mean the peptide works? No. The scorecard measures the provider, not the molecule. Even the top-scoring provider cannot offer FDA approval for these peptides in gut conditions, because none exists. A high score indicates an accountable, supervised path to the compound. That is a separate question from whether the compound is effective.

What about BPC-157 specifically? BPC-157 carries the largest preclinical file in this category and the most contested regulatory status, having been flagged by the FDA as not meeting the standard for compounding. A high-scoring provider may decline to supply it on those grounds, which is exactly what the gating criterion is designed to capture. A declined request from a supervised provider signals the framework working as intended, not failing.

Does larazotide’s Phase 2 result mean it’s available? Reaching Phase 2 is not the same as approval. Larazotide met its primary endpoint at 0.5 mg in a Phase 2 celiac disease trial (PMID 25683116), but its pivotal Phase 3 program was discontinued in 2022, according to the Celiac Disease Foundation, and it remains unapproved by the FDA. It has the strongest clinical track record of any compound discussed here, and it still falls short of an approved therapy.

References

1. Sikiric P, Seiwerth S, Rucman R, et al. “Stress in Gastrointestinal Tract and Stable Gastric Pentadecapeptide BPC 157. Finally, do we have a Solution?” Current Pharmaceutical Design. 2017. PMID: 28228068. https://pubmed.ncbi.nlm.nih.gov/28228068/ (Review; preclinical/animal evidence for BPC-157 in the GI tract.)
2. Dalmasso G, Charrier-Hisamuddin L, Nguyen HT, et al. “PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation.” Gastroenterology. 2008. PMID: 18061177. https://pubmed.ncbi.nlm.nih.gov/18061177/ (Cell-culture and mouse colitis models; preclinical.)
3. “Melanocortin-derived tripeptide KPV has anti-inflammatory potential in murine models of inflammatory bowel disease.” Inflammatory Bowel Diseases. 2008. PMID: 18092346. (Murine IBD models; preclinical.)
4. Leffler DA, Kelly CP, Green PHR, et al. “Larazotide acetate for persistent symptoms of celiac disease despite a gluten-free diet: a randomized controlled trial.” Gastroenterology. 2015. PMID: 25683116. (Phase 2 human RCT; 0.5 mg dose met primary endpoint.)
5. “Larazotide acetate for treatment of celiac disease: A systematic review and meta-analysis of randomized controlled trials.” Clinical Research in Hepatology and Gastroenterology. 2022. PMID: 34339872. (Systematic review of larazotide RCTs; more trials called for.)
6. Abad C, Martinez C, Juarranz MG, et al. “Therapeutic effects of vasoactive intestinal peptide in the trinitrobenzene sulfonic acid mice model of Crohn’s disease.” Gastroenterology. 2003. PMID: 12671893. (TNBS mouse colitis model; preclinical.)
7. Celiac Disease Foundation. “9 Meters Discontinues Phase 3 Clinical Trial for Potential Celiac Disease Drug Larazotide.” June 21, 2022. (Confirms Phase 3 larazotide trial discontinued; not FDA-approved.)

Written by Bianca Zamora, evidence reviewer. Last reviewed February 2026.

Informational, not clinical advice. Check with a healthcare professional before beginning anything.